These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25877724)

  • 1. The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis.
    Kowalec K; Carleton B; Tremlett H
    Mult Scler Relat Disord; 2013 Jul; 2(3):183-92. PubMed ID: 25877724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: using monoclonal antibodies to treat multiple sclerosis.
    Hohlfeld R; Wekerle H
    Nat Clin Pract Neurol; 2005 Nov; 1(1):34-44. PubMed ID: 16932490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.
    Wingerchuk DM
    Expert Rev Neurother; 2006 Mar; 6(3):333-46. PubMed ID: 16533138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics and active surveillance for serious adverse drug reactions in children.
    Loo TT; Ross CJ; Sistonen J; Visscher H; Madadi P; Koren G; Hayden MR; Carleton BC
    Pharmacogenomics; 2010 Sep; 11(9):1269-85. PubMed ID: 20860467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY; Constantinescu CS
    Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E; Louapre C; Lubetzki C; Papeix C
    Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current role of mitoxantrone in the treatment of multiple sclerosis.
    Cocco E; Marrosu MG
    Expert Rev Neurother; 2014 Jun; 14(6):607-16. PubMed ID: 24834466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for the use of mitoxantrone in multiple sclerosis.
    Edan G; Morrissey S; Le Page E
    J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [[Natalizumab therapy, 2013].
    Karácsony M; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango.
    Gupta S; Weinstock-Guttman B
    Expert Opin Biol Ther; 2014 Jan; 14(1):115-26. PubMed ID: 24289270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J
    Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.
    Grossman I; Knappertz V; Laifenfeld D; Ross C; Zeskind B; Kolitz S; Ladkani D; Hayardeny L; Loupe P; Laufer R; Hayden M
    Prog Neurobiol; 2017 May; 152():114-130. PubMed ID: 26952809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Disease modifying therapies in multiple sclerosis].
    Fukaura H
    Nihon Rinsho; 2014 Nov; 72(11):2015-22. PubMed ID: 25518387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the treatment of relapsing-remitting multiple sclerosis.
    Tanasescu R; Ionete C; Chou IJ; Constantinescu CS
    Biomed J; 2014; 37(2):41-9. PubMed ID: 24732658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.